Compositions and methods for suppressing or reducing systemic immune response in a subject
AssigneeThe Trustees of the University of Pennsylvania
InventorTaku Kambayashi
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof.
Claims16
A method of increasing systemic regulatory T cell (Treg) levels in a subject, the method comprising:
- topically administering to the subject a pharmaceutically effective amount of a composition consisting essentially of a vitamin D3 analog, wherein the vitamin D3 analog is 26,27-cyclo-22-ene-1α,24S-dihydroxyvitamin D3 (MC903 or calcipotriol) and at least one pharmaceutically acceptable excipient,
- whereby systemic Treg levels are increased in the subject, wherein the vitamin D3 analog is the only biologically active agent administered to the subject;
- and
- wherein the subject is afflicted with an inflammatory disease selected from the group consisting of type I diabetes, type II diabetes, atherosclerosis, multiple sclerosis, and rheumatoid arthritis.
A method of suppressing or reducing systemic immune response in a subject, the method comprising:
- topically administering to the subject a pharmaceutically effective amount of a composition consisting essentially of a vitamin D3 analog and at least one pharmaceutically acceptable excipient, wherein the vitamin D3 analog is 26,27-cyclo-22-ene-1α,24S-dihydroxyvitamin D3 (MC903 or calcipotriol),
- whereby the systemic immune response in the subject is suppressed or reduced, wherein the vitamin D3 analog is the only biologically active agent administered to the subject;
- and
- wherein the subject is afflicted with an inflammatory disease selected from the group consisting of type I diabetes, type II diabetes, atherosclerosis, multiple sclerosis, and rheumatoid arthritis.
A method of treating a systemic inflammatory disease or disorder in a subject, the method comprising:
- topically administering to the subject in need thereof a pharmaceutically effective amount of a composition consisting essentially of a vitamin D3 analog and at least one pharmaceutically acceptable excipient, wherein the vitamin D3 analog is 26,27-cyclo-22-ene-1α,24S-dihydroxyvitamin D3 (MC903 or calcipotriol), wherein the vitamin D3 analog is the only biologically active agent administered to the subject;
- and
- wherein the disease or disorder is selected from the group consisting of type I diabetes, type II diabetes, atherosclerosis, multiple sclerosis, and rheumatoid arthritis.
Dependencies are inferred from the claim text.